Filing Flows

Filing Flows › Companies › aTYR Pharma › Cash flow

aTYR Pharma cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$9.6M in Q3 2026 · −$43.9M over twelve months

Operating cash flow−$9.5M
Capital spending−$45K
Free cash flow−$9.6M

Analysis

In Q3 2026, aTYR Pharma generated −$9.5M of operating cash flow and spent $45K on capital projects, leaving free cash flow of −$9.6M. That is $11.0M more than in Q3 2025 (−$20.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$43.6M; the largest uses were operating cash flow ($43.6M), net borrowing (+) / repaid (−) ($540K), capital spending ($287K); besides operations, cash came from other investing ($49.3M), other financing ($911K); the cash balance rose by $5.8M.

Operating cash flow was −$9.5M against net income of −$18.3M. The largest differences: payables +$5.2M, stock-based pay +$2.6M, prepaid and other assets −$364K.

Free cash flow

aTYR Pharma: free cash flow by quarteraTYR Pharma: free cash flow by quarter−$13.2MQ4 2024−$15.4MQ1 2025−$13.9MQ2 2025−$20.5MQ3 2025−$12.2MQ4 2025−$12.7MQ1 2026−$9.4MQ2 2026−$9.6MQ3 2026
Operating cash flow less capital spending.
aTYR Pharma: operating cash flow against capital spendingaTYR Pharma: operating cash flow against capital spendingOperating cash flowCapital spending−$13.1M$25KQ4 2024−$15.4M$0Q1 2025−$13.9M$9KQ2 2025−$20.5M$37KQ3 2025−$12.2M$31KQ4 2025−$12.5M$138KQ1 2026−$9.4M$73KQ2 2026−$9.5M$45KQ3 2026
Latest (Q3 2026): Operating cash flow −$9.5M, Capital spending $45K.

Capital allocation, year by year

aTYR Pharma: where the cash came from (up) and went (down), by fiscal yearaTYR Pharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$33.1MFY2021: Shares issued $62KFY2021: Asset sales $50KFY2021: Capital spending −$192K$112KFY2021FY2022: Operating cash flow −$41.9MFY2022: Net borrowing −$66KFY2022: Shares issued $1KFY2022: Asset sales $179KFY2022: Capital spending −$1.6M$180KFY2022FY2023: Operating cash flow −$33.2MFY2023: Net borrowing −$394KFY2023: Asset sales $15KFY2023: Capital spending −$4.2M$15KFY2023FY2024: Operating cash flow −$69.1MFY2024: Net borrowing −$497KFY2024: Asset sales $7KFY2024: Capital spending −$65K$7KFY2024FY2025: Operating cash flow −$62.0MFY2025: Net borrowing −$539KFY2025: Shares issued $19KFY2025: Asset sales $12KFY2025: Capital spending −$77K$31KFY2025
Over these 5 years operating cash flow totalled −$239M; the largest uses were operating cash flow ($239M) and capital spending ($6.2M). Cash-flow statements as filed.

Where the cash came from and went

aTYR Pharma: sources (+) and uses (−) of cash, Q3 2026aTYR Pharma: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$9.5MOther investing$5.8MCash drawn (+) / kept (−)$3.0MOther financing$887KNet borrowing (+) / repaid (−)−$114KCapital spending−$45K
aTYR Pharma: sources (+) and uses (−) of cash, TTM to Q3 2026aTYR Pharma: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing$49.3MOperating cash flow−$43.6MCash drawn (+) / kept (−)−$5.8MOther financing$911KNet borrowing (+) / repaid (−)−$540KCapital spending−$287K

From profit to cash

aTYR Pharma: net income to operating cash flow, Q3 2026aTYR Pharma: net income to operating cash flow, Q3 2026Net income−$18.3MDepreciation & amortization$171KStock-based pay$2.6MPayables$5.2MPrepaid and other assets−$364KOperating cash flow−$9.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$9.5M−$45K−$114K—$3.0M−$9.6M
Q2 2026−$9.4M−$73K−$145K—−$5.8M−$9.4M
Q1 2026−$12.5M−$138K−$142K—$1.2M−$12.7M
Q4 2025−$12.2M−$31K−$139K—−$4.1M−$12.2M
Q3 2025−$20.5M−$37K−$136K—$11.2M−$20.5M
Q2 2025−$13.9M−$9K−$133K$17K−$7.3M−$13.9M
Q1 2025−$15.4M—−$131K$2K$1.2M−$15.4M
Q4 2024−$13.1M−$25K−$128K—$378K−$13.2M

aTYR Pharma: income statement and cash flow

aTYR Pharma, Q3 2025: revenue $190K. The chart follows the revenue to costs, profit and cash.

aTYR Pharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.